The stock price of Relmada Therapeutics Inc (NASDAQ: RLMD) has surged by 12.21 when compared to previous closing price of 3.03, but the company has seen a 21.00% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-16 that NEW YORK, Sept. 16, 2024 /PRNewswire/ — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ: RLMD) breached their fiduciary duties to shareholders.
Is It Worth Investing in Relmada Therapeutics Inc (NASDAQ: RLMD) Right Now?
The stock has a 36-month beta value of 0.50. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RLMD is 25.16M, and at present, short sellers hold a 4.79% of that float. On September 17, 2024, the average trading volume of RLMD was 127.04K shares.
RLMD’s Market Performance
RLMD stock saw an increase of 21.00% in the past week, with a monthly gain of 36.00% and a quarterly increase of 13.33%. The volatility ratio for the week is 13.07%, and the volatility levels for the last 30 days are 10.99% for Relmada Therapeutics Inc (RLMD). The simple moving average for the last 20 days is 22.24% for RLMD stock, with a simple moving average of -10.11% for the last 200 days.
Analysts’ Opinion of RLMD
Goldman, on the other hand, stated in their research note that they expect to see RLMD reach a price target of $2, previously predicting the price at $3. The rating they have provided for RLMD stocks is “Sell” according to the report published on June 05th, 2024.
Truist gave a rating of “Hold” to RLMD, setting the target price at $10 in the report published on October 14th of the previous year.
RLMD Trading at 5.59% from the 50-Day Moving Average
After a stumble in the market that brought RLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.92% of loss for the given period.
Volatility was left at 10.99%, however, over the last 30 days, the volatility rate increased by 13.07%, as shares surge +14.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.76% upper at present.
During the last 5 trading sessions, RLMD rose by +17.79%, which changed the moving average for the period of 200-days by +31.87% in comparison to the 20-day moving average, which settled at $2.80. In addition, Relmada Therapeutics Inc saw -17.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLMD starting from TRAVERSA SERGIO, who purchase 51,407 shares at the price of $2.99 back on Sep 11 ’24. After this action, TRAVERSA SERGIO now owns 384,024 shares of Relmada Therapeutics Inc, valued at $153,707 using the latest closing price.
TRAVERSA SERGIO, the Chief Executive Officer of Relmada Therapeutics Inc, purchase 55,579 shares at $2.71 during a trade that took place back on Sep 09 ’24, which means that TRAVERSA SERGIO is holding 299,603 shares at $150,619 based on the most recent closing price.
Stock Fundamentals for RLMD
The total capital return value is set at -1.49. Equity return is now at value -100.40, with -89.88 for asset returns.
Currently, EBITDA for the company is -103.7 million with net debt to EBITDA at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.44.
Conclusion
To sum up, Relmada Therapeutics Inc (RLMD) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
